Severity of new pressure ulcers ‐ Stage 1 · individuals at risk of pressure ulcer development
Waterlow pressure ulcer risk assessment showed no clear difference in severity of new pressure ulcers ‐ Stage 1 compared with pressure ulcer risk assessment using clinical judgement (low certainty).
1 finding from 1 review
Severity of new pressure ulcers ‐ Stage 2 · individuals at risk of pressure ulcer development
Waterlow pressure ulcer risk assessment showed no clear difference in severity of new pressure ulcers ‐ Stage 2 compared with pressure ulcer risk assessment using clinical judgement (low certainty).
1 finding from 1 review
Time to ulcer development Pressure ulcer prevalence · individuals at risk of pressure ulcer development
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Maternal death · women with eclampsia
It is very uncertain whether treatment of eclampsia: lower‐dose regimens changes maternal death compared with standard‐dose regimens (very low certainty).
1 finding from 1 review
Other neonatal morbidity · women with eclampsia
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Side effects · women with eclampsia
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Functioning: clinically important change in general functioning, as defined by individual studies · patients with schizophrenia
1 finding from 1 review
Adverse effect: clinically important adverse effect (weight ‐ BMI) · patients with schizophrenia
1 finding from 1 review
Service utilisation outcomes: hospital admission or days in hospital · patients with schizophrenia
1 finding from 1 review
Service use: time to hospitalisation · patients with schizophrenia
1 finding from 1 review
Quality of life: clinically important change in quality of life · patients with schizophrenia
1 finding from 1 review
Global state: clinically important change in global state · patients with schizophrenia
1 finding from 1 review
Mental state: clinically important response, as defined by individual studies * · patients with schizophrenia
1 finding from 1 review
Global state: clinically important change in global state · patients with schizophrenia
1 finding from 1 review
Mental state: clinically important response in mental state BPRS score >30% change · patients with schizophrenia
Clozapine: low dose (150 mg/day to 300 mg/day) showed no clear difference in mental state: clinically important response in mental state BPRS… compared with standard dose (301 mg/day to 600 mg/day) (low certainty).
1 finding from 1 review
Functioning: clinically important change in general functioning, as defined by individual studies · patients with schizophrenia
1 finding from 1 review
Adverse effect: clinically important adverse effect (weight ‐ BMI) · patients with schizophrenia
1 finding from 1 review
Service utilisation outcomes: hospital admission or days in hospital · patients with schizophrenia
1 finding from 1 review
Service use: time to hospitalisation · patients with schizophrenia
1 finding from 1 review
Quality of life: clinically important change in quality of life · patients with schizophrenia
1 finding from 1 review